Science

Talha Badar: Venetoclax plus 3+7 for newly diagnosed acute myeloid leukemia

Talha Badar/X

Apr 26, 2025, 14:34

Talha Badar: Venetoclax plus 3+7 for newly diagnosed acute myeloid leukemia

Talha Badar, Hematology/Oncology specialist at Mayo Clinic, shared a post on X about a paper by Ioannis Mantzaris et al. published in Blood:

“Venetoclax plus 3+7 for newly diagnosed acute myeloid leukemia: results of a phase 1b study

Ven given for 8, 11 and 14 days with 3+7.
DNR at 90 mg/m2 in < 60 yrs.
58% with intermediate risk AML, 26.5% adverse risk.
NPM1m 38%.
cCR > 80%.
NS difference in CR with 8, 11 or 14 days of Ven.
mEFS and OS NR (median fu 9.6 mo).”

“Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study”

Authors: Ioannis Mantzaris, Mendel Goldfinger, Matan Uriel, Aditi Shastri, Nishi Shah, Mimi Kim, Dennis Cooper, Amit Verma, Marina Konopleva, Eric Feldman et al.

Talha Badar: Venetoclax plus 3+7 for newly diagnosed acute myeloid leukemia

More posts featuring Talha Badar.

Acute Myeloid Leukemia Aditi Shastri Amit Verma AML cancer Dennis Cooper Eric Feldman Ioannis Mantzaris Marina Konopleva Matan Uriel Mendel Goldfinger Mimi Kim Nishi Shah OncoDaily Oncology Talha Badar

10 Caring Notes from Pope Francis on Healthcare

FDA Approves Penpulimab for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma

Senate President Passes Away After Brave Battle with Cancer: Dominick J. Ruggerio

Where to Study to Become ASCO President: 2025 Institutional Rankings

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma